News Image

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

Provided By GlobeNewswire

Last update: May 14, 2025

ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial

Read more at globenewswire.com

APREA THERAPEUTICS INC

NASDAQ:APRE (7/3/2025, 8:28:02 PM)

1.74

+0.04 (+2.35%)



Find more stocks in the Stock Screener

Follow ChartMill for more